{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:28:20Z","timestamp":1769552900002,"version":"3.49.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.cca.2014.11.004","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T03:30:18Z","timestamp":1415331018000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Biomarkers for neuromyelitis optica"],"prefix":"10.1016","volume":"440","author":[{"given":"Kuo-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Sun","family":"Ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Kuo","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2014.11.004_bb0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(02)68218-2","article-title":"On the ophthalmoscopic signs of spinal disease","volume":"95","author":"Clifford","year":"1870","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2014.11.004_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.cca.2014.11.004_bb0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","article-title":"The prevalence of neuromyelitis optica in South East Wales","volume":"19","author":"Cossburn","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0030","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-Gomez","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.neurol.2009.02.012","article-title":"Descriptive epidemiology of neuromyelitis optica in the Caribbean basin","volume":"165","author":"Cabre","year":"2009","journal-title":"Rev Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/1352458513495580","article-title":"The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project","volume":"20","author":"Papais-Alvarenga","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0050","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0060","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2011.01.007","article-title":"Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders","volume":"234","author":"Dujmovic","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0070","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneurol.2009.188","article-title":"Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells","volume":"66","author":"Hinson","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0075","doi-asserted-by":"crossref","first-page":"146219","DOI":"10.1155\/2013\/146219","article-title":"Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica","volume":"2013","author":"Chanson","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0080","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrn1252","article-title":"The molecular basis of water transport in the brain","volume":"4","author":"Amiry-Moghaddam","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.cca.2014.11.004_bb0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","article-title":"Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain","volume":"17","author":"Nielsen","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.cca.2014.11.004_bb0090","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1096\/fj.13-231274","article-title":"Greatly improved survival and neuroprotection in aquaporin-4-knockout mice following global cerebral ischemia","volume":"28","author":"Katada","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.cca.2014.11.004_bb0095","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1074\/jbc.M413627200","article-title":"Aquaporin-4 gene disruption in mice reduces brain swelling and mortality in pneumococcal meningitis","volume":"280","author":"Papadopoulos","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2014.11.004_bb0100","doi-asserted-by":"crossref","first-page":"17815","DOI":"10.1073\/pnas.1110655108","article-title":"Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood\u2013brain water uptake and confers barrier function on perivascular astrocyte endfeet","volume":"108","author":"Haj-Yasein","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.11.004_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/72256","article-title":"Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke","volume":"6","author":"Manley","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.cca.2014.11.004_bb0110","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1096\/fj.04-1723fje","article-title":"Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema","volume":"18","author":"Papadopoulos","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.cca.2014.11.004_bb0115","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/sj.jcbfm.9600306","article-title":"Accelerated progression of kaolin-induced hydrocephalus in aquaporin-4-deficient mice","volume":"26","author":"Bloch","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.cca.2014.11.004_bb0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/glia.20318","article-title":"Increased seizure duration and slowed potassium kinetics in mice lacking aquaporin-4 water channels","volume":"53","author":"Binder","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.cca.2014.11.004_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0079-6123(08)00446-9","article-title":"Potential utility of aquaporin modulators for therapy of brain disorders","volume":"170","author":"Papadopoulos","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.cca.2014.11.004_bb0130","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2014.11.004_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000322740","article-title":"The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan","volume":"65","author":"Wang","year":"2011","journal-title":"Eur Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0140","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.wnl.0000256822.01222.bd","article-title":"NMO-IgG in the diagnosis of neuromyelitis optica","volume":"68","author":"Jarius","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0145","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/1352458507084595","article-title":"NMO-IgG and Devic's neuromyelitis optica: a French experience","volume":"14","author":"Marignier","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp.2005.080390","article-title":"Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG","volume":"77","author":"Nakashima","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cca.2014.11.004_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1352458512451659","article-title":"Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies","volume":"19","author":"Chang","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0160","first-page":"99","article-title":"Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays","volume":"15","author":"Waters","year":"2008","journal-title":"Int MS J"},{"key":"10.1016\/j.cca.2014.11.004_bb0165","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1371\/journal.pmed.0040133","article-title":"Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica","volume":"4","author":"Paul","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.cca.2014.11.004_bb0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2008.03.009","article-title":"Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay","volume":"196","author":"Hayakawa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0175","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"key":"10.1016\/j.cca.2014.11.004_bb0180","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1073\/pnas.93.20.10908","article-title":"The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain","volume":"93","author":"Lu","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.11.004_bb0185","doi-asserted-by":"crossref","first-page":"13609","DOI":"10.1073\/pnas.2235843100","article-title":"Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms","volume":"100","author":"Furman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.11.004_bb0190","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/glia.20855","article-title":"Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies","volume":"57","author":"Nicchia","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.cca.2014.11.004_bb0195","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.11.004_bb0200","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2014.11.004_bb0205","doi-asserted-by":"crossref","first-page":"e10455","DOI":"10.1371\/journal.pone.0010455","article-title":"Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica","volume":"5","author":"Mader","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cca.2014.11.004_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.cca.2014.11.004_bb0215","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","article-title":"NMO-IgG detected in CSF in seronegative neuromyelitis optica","volume":"72","author":"Klawiter","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0220","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0225","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458511424590","article-title":"Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0230","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/brain\/awm027","article-title":"Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese","volume":"130","author":"Matsuoka","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0235","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jns.2008.08.015","article-title":"Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection","volume":"276","author":"Heerlein","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.cca.2014.11.004_bb0240","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1542\/peds.2007-2758","article-title":"Spectrum of pediatric neuromyelitis optica","volume":"122","author":"Lotze","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.cca.2014.11.004_bb0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jnnp-2012-302925","article-title":"Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status","volume":"84","author":"Yoshimura","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cca.2014.11.004_bb0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","article-title":"Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0255","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0260","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0265","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0270","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/WNR.0b013e32832776f4","article-title":"Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum","volume":"20","author":"Kinoshita","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.cca.2014.11.004_bb0275","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","article-title":"Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG","volume":"127","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.cca.2014.11.004_bb0280","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jneuroim.2009.07.014","article-title":"Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study","volume":"215","author":"Sabater","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0290","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0295","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/WNL.54.6.1391","article-title":"Steroid-responsive Devic's variant in Sjogren's syndrome","volume":"54","author":"Mochizuki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0300","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1191\/096120399678847696","article-title":"Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus","volume":"8","author":"Bonnet","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.cca.2014.11.004_bb0305","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.26.11.1066","article-title":"A case of neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus. Clinicopathologic report and review of the literature","volume":"26","author":"April","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0310","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0315","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.410440408","article-title":"A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?","volume":"44","author":"Karussis","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0320","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00041327-199712000-00008","article-title":"A case of bilateral optic neuropathy and recurrent transverse myelopathy associated with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA)","volume":"17","author":"Harada","year":"1997","journal-title":"J Neuro Ophthalmol"},{"key":"10.1016\/j.cca.2014.11.004_bb0325","doi-asserted-by":"crossref","first-page":"e74773","DOI":"10.1371\/journal.pone.0074773","article-title":"Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders","volume":"8","author":"Tzartos","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cca.2014.11.004_bb0330","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0335","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.11.004_bb0340","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine\u201440years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0350","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cca.2014.11.004_bb0355","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"Icoz","year":"2010","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.cca.2014.11.004_bb0360","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0365","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10875-012-9837-2","article-title":"Increased plasma interleukin-32 expression in patients with neuromyelitis optica","volume":"33","author":"Wang","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0370","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1212\/01.WNL.0000148481.80152.BF","article-title":"Activation of humoral immunity and eosinophils in neuromyelitis optica","volume":"63","author":"Correale","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0375","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","article-title":"The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients","volume":"33","author":"Linhares","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0380","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.11.004_bb0385","doi-asserted-by":"crossref","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cca.2014.11.004_bb0390","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0395","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp-2012-304039","article-title":"CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica","volume":"84","author":"Uzawa","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cca.2014.11.004_bb0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000345994","article-title":"Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis","volume":"20","author":"Wang","year":"2013","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.cca.2014.11.004_bb0405","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","article-title":"Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica","volume":"19","author":"Wang","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.cca.2014.11.004_bb0410","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83","author":"Uzawa","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cca.2014.11.004_bb0415","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jneuroim.2011.03.009","article-title":"Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis","volume":"234","author":"Li","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0420","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cyto.2013.07.019","article-title":"Post-acute serum eosinophil and neutrophil-associated cytokine\/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms \u2014 a pilot study","volume":"64","author":"Michael","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.cca.2014.11.004_bb0425","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jocn.2011.01.031","article-title":"Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse","volume":"18","author":"Wang","year":"2011","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.cca.2014.11.004_bb0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/jir.2012.0040","article-title":"Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis","volume":"33","author":"Wang","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.cca.2014.11.004_bb0435","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.neuroscience.2012.08.041","article-title":"Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica","volume":"226","author":"Wang","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.cca.2014.11.004_bb0440","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","article-title":"Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein","volume":"18","author":"Herges","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0445","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.04.009","article-title":"Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood\u2013brain barrier","volume":"236","author":"Hosokawa","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0450","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.0b013e3181c1deb9","article-title":"Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis","volume":"73","author":"Yanagawa","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0455","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.cca.2014.11.004_bb0460","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/1352458509104595","article-title":"Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese","volume":"15","author":"Matsushita","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0465","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bst0250625","article-title":"Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes","volume":"25","author":"Adorini","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.cca.2014.11.004_bb0470","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1590\/S0004-282X2008000500013","article-title":"Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica","volume":"66","author":"Alves-Leon","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.cca.2014.11.004_bb0475","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0480","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.182.4.1169","article-title":"Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo","volume":"182","author":"Collins","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.cca.2014.11.004_bb0485","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneuroim.2003.12.010","article-title":"CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis","volume":"149","author":"Narikawa","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0490","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1084\/jem.184.3.963","article-title":"Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes","volume":"184","author":"Loetscher","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.cca.2014.11.004_bb0495","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.287.5454.860","article-title":"Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity","volume":"287","author":"Ashkar","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.cca.2014.11.004_bb0500","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2013.07.005","article-title":"Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica","volume":"263","author":"Shimizu","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0505","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0510","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cca.2014.11.004_bb0515","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/jnr.21211","article-title":"S100B in neuropathologic states: the CRP of the brain?","volume":"85","author":"Sen","year":"2007","journal-title":"J Neurosci Res"},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2014.11.004_bb0520","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10875-012-9796-7","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Wingerchuk","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0525","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0530","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/sji.12132","article-title":"Increased soluble C5b-9 in CSF of neuromyelitis optica","volume":"79","author":"Wang","year":"2014","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0535","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5223(99)70183-2","article-title":"Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation","volume":"118","author":"Rinder","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cca.2014.11.004_bb0540","first-page":"163","article-title":"HMGB1 and its physiological and pathological roles","volume":"113","author":"Naglova","year":"2012","journal-title":"Bratisl Lek Listy"},{"issue":"Suppl.","key":"10.1016\/j.cca.2014.11.004_bb0545","first-page":"S97","article-title":"Haptoglobin phenotypes in health and disorders","volume":"121","author":"Sadrzadeh","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cca.2014.11.004_bb0550","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2012.12.008","article-title":"Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis","volume":"417","author":"Chang","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.11.004_bb0555","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1359-6101(02)00045-X","article-title":"Macrophage inflammatory protein-1","volume":"13","author":"Menten","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cca.2014.11.004_bb0560","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneurol.2011.148","article-title":"Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood\u2013brain barrier breakdown in neuromyelitis optica","volume":"68","author":"Uzawa","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0565","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1074-7613(01)00257-6","article-title":"CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity","volume":"16","author":"Ansel","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.cca.2014.11.004_bb0570","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2011.10.001","article-title":"Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica","volume":"240\u2013241","author":"Zhong","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cca.2014.11.004_bb0575","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0580","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1515\/REVNEURO.2003.14.4.369","article-title":"Neurobehavioral characteristics of mice with modified intermediate filament genes","volume":"14","author":"Lalonde","year":"2003","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.cca.2014.11.004_bb0585","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/01.wnl.0000256820.26489.17","article-title":"High CSF neurofilament heavy chain levels in neuromyelitis optica","volume":"68","author":"Miyazawa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0590","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/1352458513504638","article-title":"Serum analysis by 1H Nuclear Magnetic Resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis","volume":"20","author":"Moussallieh","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0595","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","article-title":"Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)","volume":"31","author":"Bakker","year":"2004","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.cca.2014.11.004_bb0600","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0605","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0610","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0615","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0620","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0625","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.cca.2014.11.004_bb0630","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0635","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0640","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0645","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","article-title":"Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody","volume":"73","author":"Tradtrantip","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0650","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202939","article-title":"Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab","volume":"2014","author":"Lauenstein","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cca.2014.11.004_bb0655","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2014.11.004_bb0660","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0665","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cca.2014.11.004_bb0670","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cca.2014.11.004_bb0675","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114004963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114004963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T23:58:14Z","timestamp":1565999894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898114004963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":135,"alternative-id":["S0009898114004963"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2014.11.004","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers for neuromyelitis optica","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2014.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}